Search

everythinglearnresearchcommunity

for

Search:↓

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

The combination of encorafenib and binimetinib caused few skin issues.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

The combination treatment showed a higher response rate but no significant survival benefits.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.

The drug combination was safe and showed promise in treating advanced tumors.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Sorafenib can cause a unique skin reaction.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.

Afatinib often causes skin problems that need proactive management.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Promising cancer treatments were found, but the manufacturer closed.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

Sorafenib often causes skin side effects, indicating effective cancer treatment.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.